Gastrointestinal Cancer | Norton Healthcare

Indication: Gastrointestinal Cancer

A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with R

Sub-indication: Gastrointestinal Cancer

Drug Study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: Hutchison MediPharma Limited

Learn more at ClinicalTrials.gov

Email for more information: GI-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.